Featured 13F manager
Palo Alto Investors LP Palo Alto Investors
Palo Alto, CA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $724M
- 52 Positions
- 2026 Q2
- +10.7% QoQ
- Top 5 37.7%
Palo Alto Investors files Palo Alto Investors LP as a Form 13F. The latest book is 2026 Q2 at $724M, up 10.7% QoQ, led by Ptc Therapeutics, Acadia Pharmaceuticals, and Insmed.
Portfolio
top 5 37.7% · top 10 61.3%
- PTC - Ptc Therapeutics 10.4%
- ACAD - Acadia Pharmaceuticals 10.0%
- INSM - Insmed 6.1%
- MIRM - Mirum Pharmaceuticals 5.6%
- ANAB - Anaptysbio 5.6%
- BMRN - Biomarin Pharmaceutical 5.4%
- DYN - Dyne Therapeutics 5.1%
- UTHR - United Therapeutics 4.7%
- IRON - Disc Medicine 4.2%
- BIIB - Biogen 4.2%
- IOVA - Iovance Biotherapeutics 3.0%
- RARE — 2.8%
- Other 32.9%
AUM over time
Book
| BMRN - Biomarin Pharmaceutical | 12.49% | Hold | 2,212,950 | $88.35 | $196M | — | — |
| Abiomed | 11.91% | Reduce −5.6% | 519,033 | $359.17 | $186M | −30,787 | +$7M |
| INSM - Insmed | 10.49% | Add +0.1% | 6,025,706 | $27.24 | $164M | +6,600 | −$2M |
| UTHR - United Therapeutics | 9.49% | Hold | 687,206 | $216.08 | $148M | — | — |
| FOLD - Amicus | 7.47% | Hold | 10,114,043 | $11.55 | $117M | — | — |
| Staar Surgical | 6.65% | Hold | 1,140,511 | $91.30 | $104M | — | — |
| BIIB - Biogen | 5.90% | Add +6.5% | 385,000 | $239.92 | $92M | +23,400 | −$10M |
| PRTA - Prothena | 5.32% | Hold | 1,685,282 | $49.40 | $83M | — | — |
| Revance Therapeutics | 4.56% | Add +36.5% | 4,369,366 | $16.32 | $71M | +1,167,500 | −$18M |
| ACAD - Acadia Pharmaceuticals | 3.49% | Hold | 2,337,877 | $23.34 | $55M | — | — |
| VNDA - Vanda Pharmaceuticals | 2.84% | Reduce −25.3% | 2,834,244 | $15.69 | $44M | −957,561 | −$21M |
| EHTH - Ehealth | 2.63% | Add +41.0% | 1,615,570 | $25.50 | $41M | +469,700 | −$5M |
| ALGN - Align Technology | 2.33% | Hold | 55,405 | $657.18 | $36M | — | — |
| Karyopharm Therapeutics | 2.25% | Add +1.6% | 5,470,452 | $6.43 | $35M | +87,400 | +$4M |
| Sage Therapeutics | 2.13% | Add +26.5% | 781,730 | $42.54 | $33M | +163,800 | +$6M |
| Gritstone Oncology | 1.94% | Hold | 2,356,282 | $12.86 | $30M | — | — |
| Gossamer Bio | 1.28% | Hold | 1,772,950 | $11.31 | $20M | — | — |
| ALKS - Alkermes | 1.12% | Add +27.9% | 754,200 | $23.26 | $18M | +164,300 | −$650K |
| ANAB - Anaptysbio | 0.97% | Hold | 436,592 | $34.75 | $15M | — | — |
| Epizyme | 0.88% | Reduce −20.0% | 5,485,213 | $2.50 | $14M | −1,371,300 | −$21M |
| SNDX - Syndax Pharmaceuticals | 0.84% | Add +34.6% | 598,900 | $21.89 | $13M | +154,000 | +$5M |
| Kezar Life Sciences | 0.70% | Hold | 656,200 | $16.72 | $11M | — | — |
| Clovis Oncology | 0.69% | Reduce −10.9% | 3,997,826 | $2.71 | $11M | −486,585 | −$9M |
| CYTK - Cytokinetics | 0.36% | Hold | 123,686 | $45.58 | $6M | — | — |
| TVTX - Travere Therapeutics | 0.33% | Hold | 166,069 | $31.04 | $5M | — | — |
| Zogenix | 0.19% | Reduce −14.4% | 183,800 | $16.25 | $3M | −30,900 | −$274K |
| Magenta Therapeutics | 0.12% | Hold | 432,300 | $4.43 | $2M | — | — |
| NVAX - Novavax | 0.11% | New | 12,500 | $143.04 | $2M | +12,500 | +$2M |
| Rigel Pharmaceuticals | 0.11% | Hold | 652,395 | $2.65 | $2M | — | — |
| AZNN — | 0.11% | Reduce −85.5% | 29,260 | $58.24 | $2M | −172,229 | −$10M |
| MIRM - Mirum Pharmaceuticals | 0.07% | New | 64,700 | $15.95 | $1M | +64,700 | +$1M |
| Alimera Sciences | 0.07% | Hold | 200,919 | $5.13 | $1M | — | — |
| Kaleido Biosciences | 0.05% | Reduce −56.6% | 341,030 | $2.39 | $815K | −445,370 | −$3M |
| ALDX - Aldeyra Therapeutics | 0.04% | Hold | 160,800 | $4.00 | $643K | — | — |
| Holding | 0.03% | Hold | 27,100 | $19.04 | $516K | — | — |
| Marinus Pharmaceuticals | 0.02% | Hold | 31,330 | $11.87 | $372K | — | — |
| URGN - Urogen Pharma | 0.01% | Hold | 24,500 | $9.51 | $233K | — | — |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2021 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Dicerna Pharmaceuticals | 1.04% | Exit | 0 | $20.16 | $17M | −855,713 | −$17M |
| Puma Biotechnology | 0.59% | Exit | 0 | $7.01 | $10M | −1,392,997 | −$10M |
| Athenex | 0.06% | Exit | 0 | $3.01 | $958K | −318,200 | −$958K |
| Syros Pharmaceuticals | 0.02% | Exit | 0 | $4.47 | $360K | −80,600 | −$360K |
| Viracta Therapeutics | 0.02% | Exit | 0 | $8.01 | $266K | −33,212 | −$266K |
| Idera Pharmaceuticals | — | Exit | 0 | $1.03 | $79K | −77,044 | −$79K |
| Minerva Neurosciences | — | Exit | 0 | $1.73 | $63K | −36,319 | −$63K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 52 | $724M | +10.7% | RESTATEMENT | 8/19/2026 | 000207367926000102 |
| 2026 Q2 | 52 | $724M | — | RESTATEMENT | 8/18/2026 | 000207367926000101 |
| 2026 Q2 | 52 | $724M | — | 13F-HR | 8/17/2026 | 000207367926000096 |
| 2026 Q1 | 51 | $654M | −8.9% | 13F-HR | 5/15/2026 | 000130692326000004 |
| 2025 Q4 | 49 | $718M | +33.0% | 13F-HR | 2/17/2026 | 000130692326000002 |
| 2025 Q3 | 44 | $540M | +14.9% | 13F-HR | 11/14/2025 | 000130692325000019 |
| 2025 Q2 | 45 | $470M | −10.5% | 13F-HR | 8/14/2025 | 000130692325000016 |
| 2025 Q1 | 44 | $525M | −18.6% | 13F-HR | 5/15/2025 | 000130692325000014 |
| 2024 Q4 | 43 | $645M | −16.2% | 13F-HR | 2/14/2025 | 000130692325000010 |
| 2024 Q3 | 45 | $770M | −10.8% | 13F-HR | 11/14/2024 | 000130692324000012 |
| 2024 Q2 | 39 | $863M | −2.7% | 13F-HR | 8/14/2024 | 000130692324000010 |
| 2024 Q1 | 38 | $887M | −19.9% | 13F-HR | 5/15/2024 | 000130692324000008 |
| 2023 Q4 | 34 | $1.1B | — | RESTATEMENT | 2/15/2024 | 000130692324000007 |
| 2023 Q4 | 34 | $1.1B | +4.7% | 13F-HR | 2/14/2024 | 000130692324000002 |
| 2023 Q3 | 29 | $1.1B | −14.6% | 13F-HR | 11/14/2023 | 000130692323000014 |
| 2023 Q2 | 30 | $1.2B | +2.6% | 13F-HR | 8/14/2023 | 000130692323000012 |
| 2023 Q1 | 30 | $1.2B | +2.9% | 13F-HR | 5/15/2023 | 000130692323000011 |
| 2022 Q4 | 29 | $1.2B | −7.3% | 13F-HR | 2/14/2023 | 000130692323000009 |
| 2022 Q3 | 32 | $1.3B | +10.3% | 13F-HR | 11/14/2022 | 000130692322000016 |
| 2022 Q2 | 33 | $1.1B | −11.3% | 13F-HR | 8/15/2022 | 000130692322000015 |
| 2022 Q1 | 35 | $1.3B | −17.4% | 13F-HR | 5/16/2022 | 000130692322000014 |
| 2021 Q4 | 37 | $1.6B | −5.6% | 13F-HR | 2/14/2022 | 000130692322000004 |
| 2021 Q3 | 42 | $1.7B | — | 13F-HR | 11/15/2021 | 000130692321000026 |
About
Palo Alto Investors LP
23 processed 13Fs on this site · 2021 Q3–2026 Q2